GLP-1 / incretin class catch-all
248 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
248
Active
113
Recruiting
60
Completed
105
Sites
1,277
Countries
50
Endpoints
2,479
Composite endpoints
135
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
84
69
52
46
35
33
31
30
29
29
27
26
25
21
20
18
17
16
15
15
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
248 of 248
| Asset / Population | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT03807440DIA_CENTRAL:T2D Treatment Pattern in Central Europe | GLP-1 / incretin class catch-all Type 2 diabetes | — | — | Completed | 177 | Aug 2021 | 1 | results |
| BRIGHTEfficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist | GLP-1 / incretin class catch-all Type 2 diabetes | — | Ph 4 | Completed | 158 | Aug 2017 | 1 | results |
| SURPASS-2A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Type 2 diabetes | BMI ≥25 | Ph 3 | Completed | 127 | Jan 2021 | 9 | results |
| LixiLan-GEfficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period | Albiglutide, Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 124 | May 2018 | 5 | results |
| DUAL™ IIIThe Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy | Exenatide, GLP-1 / incretin class catch-all, Liraglutide Type 2 diabetes | BMI ≤40 | Ph 3 | Completed | 109 | Mar 2014 | 3 | results |
| NCT00635492CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy | Exenatide, GLP-1 / incretin class catch-all Type 2 diabetes | — | — | Completed | 96 | Dec 2011 | 2 | results |
| NCT05579977Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity | GLP-1 / incretin class catch-all, Lotiglipron, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥23 | Ph 2 | Terminated | 90 | Jul 2023 | 2 | results |
| STARS extendOpen-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. | GLP-1 / incretin class catch-all Gastrointestinal (gastroparesis / short bowel / pancreatitis) | — | Ph 3 | Active, not recruiting | 66 | Oct 2027 | — | |
| PRECIDENTDPREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes | Dulaglutide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide Cardiovascular disease, Type 2 diabetes | Established ASCVD/CKD | Ph 4 | Recruiting | 36 | Mar 2029 | 1 | |
| GRADEA Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes | GLP-1 / incretin class catch-all, Liraglutide Type 2 diabetes | HbA1c 6.8-8.5% | Ph 3 | Completed | 36 | Apr 2021 | 61 | results |
| NCT04952779Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea | GLP-1 / incretin class catch-all, Liraglutide Type 2 diabetes | — | — | Completed | 32 | Dec 2024 | — | |
| FLAMESFibrosis Lessens After Metabolic Surgery | GLP-1 / incretin class catch-all, Liraglutide, Semaglutide, Tirzepatide Bariatric Surgery Candidate, MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI 35-70 | Ph 4 | Recruiting | 22 | May 2029 | — | |
| NCT06833749Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis | GLP-1 / incretin class catch-all, KBP-336 Obesity / overweight, Osteoarthritis, Pain | BMI ≥30 | Ph 2 | Recruiting | 20 | Nov 2026 | — | |
| GETGOAL-XGLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin | Exenatide, GLP-1 / incretin class catch-all, Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 18 | Nov 2010 | 2 | results |
| NCT06732245Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese | GLP-1 / incretin class catch-all, NA-931, Tirzepatide Obesity / overweight | BMI ≥30 | Ph 2 | Not yet recruiting | 17 | Aug 2027 | — | |
| NCT02589626Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA | GLP-1 / incretin class catch-all Type 2 diabetes | BMI ≤40 | Ph 4 | Completed | 16 | Jun 2017 | 1 | results |
| SERENASemaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes | GLP-1 / incretin class catch-all, Semaglutide Gestational diabetes, Prediabetes / glucose intolerance | Female | Ph 3 | Recruiting | 13 | Jun 2029 | — | |
| NCT01303315TANTALUS Therapy in Type 2 Diabetic Patients Intolerant or Inadequately Responsive to GLP-1 Receptor Agonist Therapy | GLP-1 / incretin class catch-all Type 2 diabetes | BMI ≤40 | Not applicable | Terminated | 13 | Jul 2011 | — | |
| NCT05415410Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD) | GLP-1 / incretin class catch-all | — | Ph 2 | Terminated | 13 | Dec 2024 | — | results |
| SEVERALSEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY. | Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥30 | — | Completed | 11 | Nov 2023 | 14 | |
| NCT06003985Gastric Ultrasound Assessment for Patients Taking GLP1 Agonists | GLP-1 / incretin class catch-all Perioperative / gastric aspiration risk | — | — | Completed | 8 | Jan 2025 | 3 | |
| PROACTA Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2) | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight, Sarcopenia / muscle | BMI ≥30 | Ph 2 | Recruiting | 7 | Mar 2027 | — | |
| NCT02291874Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM) | GLP-1 / incretin class catch-all Type 2 diabetes | BMI ≥20 | Ph 4 | Completed | 6 | Jul 2016 | 1 | |
| MICRONThe MICRON Study - A Steno 1 Substudy | GLP-1 / incretin class catch-all Type 1 diabetes | BMI ≥35 | — | Recruiting | 5 | Jul 2028 | 1 | |
| BESTMEDBESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes | Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide Type 2 diabetes | HbA1c 7-11% | — | Unknown | 5 | Jun 2024 | 3 | |
| GLP1-TASTEChanges in Taste and Eating Habits Associated With GLP-1 Agonists in Weight Loss Patients | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Obesity / overweight | — | — | Recruiting | 4 | Jan 2027 | 1 | |
| COMBAT-PsACombination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis | GLP-1 / incretin class catch-all, Tirzepatide Obesity / overweight, Psoriasis / psoriatic arthritis | BMI ≥27 | Not applicable | Recruiting | 4 | Feb 2028 | 14 | |
| NCT00747968The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET | Exenatide, GLP-1 / incretin class catch-all Type 2 diabetes | BMI 20-45 | Ph 2/3 | Completed | 4 | Nov 2010 | 1 | |
| NCT02488057Improving Beta Cell Function in Mexican American Women With Prediabetes | GLP-1 / incretin class catch-all, Liraglutide Obesity / overweight, Prediabetes / glucose intolerance | BMI 30-42 | Ph 4 | Completed | 4 | Mar 2019 | 10 | |
| NCT05005741The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity. | Beinaglutide, Dulaglutide, GLP-1 / incretin class catch-all Obesity / overweight, Type 2 diabetes | BMI 24-35 | Ph 4 | Unknown | 4 | Dec 2023 | — | |
| DIRECTGLPDIabetes REsearCh on Patient sTratification (DIRECT): GLP-1R Agonists | Exenatide, GLP-1 / incretin class catch-all, Liraglutide Type 2 diabetes | HbA1c ≥7.5% | Not applicable | Completed | 4 | Jul 2015 | — | |
| ST2OMPSurgical or Medical Treatment | GLP-1 / incretin class catch-all Bariatric Surgery Candidate, Obesity / overweight, Type 2 diabetes | — | Ph 4 | Active, not recruiting | 3 | Dec 2026 | 1 | |
| NCT04892199Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication? | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight, Prediabetes / glucose intolerance, Psychiatric (schizophrenia / bipolar / depression), Type 2 diabetes | BMI ≥25 | Ph 4 | Active, not recruiting | 3 | Mar 2026 | 2 | |
| NCT06901245Tirzepatide in PWS, HO and GNSO | GLP-1 / incretin class catch-all, Tirzepatide Hypothalamic / syndromic obesity, Obesity / overweight | — | Ph 4 | Recruiting | 3 | Jun 2026 | — | |
| NCT07431086Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US | GLP-1 / incretin class catch-all Obesity / overweight | BMI 27-45 | Ph 2 | Recruiting | 3 | Nov 2026 | — | |
| GLICHGLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial | GLP-1 / incretin class catch-all, Semaglutide Stroke | — | Ph 2 | Not yet recruiting | 3 | Jun 2028 | — | |
| NCT00530309Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus | GLP-1 / incretin class catch-all Type 2 diabetes | BMI 20-70 | Ph 1 | Completed | 3 | Apr 2008 | 2 | |
| ECHOEnergy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity | Exenatide, GLP-1 / incretin class catch-all Hypothalamic / syndromic obesity, Obesity / overweight | BMI ≥95 | Ph 3 | Completed | 3 | Mar 2020 | — | results |
| INTENSIFYA Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates | GLP-1 / incretin class catch-all, Liraglutide Type 2 diabetes | HbA1c ≤12% | — | Completed | 3 | Dec 2020 | — | |
| NCT07127354The Impact of GLP Medication on Colonoscopy Bowel Preparation Quality | GLP-1 / incretin class catch-all Perioperative / gastric aspiration risk | — | Ph 4 | Recruiting | 3 | Aug 2026 | — | |
| NCT05756764Anti-obesity Pharmacotherapy and Inflammation | GLP-1 / incretin class catch-all, Liraglutide, Semaglutide, Tirzepatide Obesity / overweight | BMI ≥30 | — | Active, not recruiting | 2 | Jan 2026 | — | |
| POCUSGastric POCUS for Airway Management in Patients Using Glucagon-like Peptide-1 Receptor Agonist (Multicentric) | GLP-1 / incretin class catch-all Perioperative / gastric aspiration risk | — | — | Recruiting | 2 | Nov 2026 | — | |
| GEM-GLP1RAGastric Emptying With Metoclopramide in GLP-1 Agonist Patients Undergoing Elective Surgery | GLP-1 / incretin class catch-all Obesity / overweight, Perioperative / gastric aspiration risk | — | Ph 4 | Not yet recruiting | 2 | May 2026 | 11 | |
| NCT07444073Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Obesity / overweight | BMI ≥27.5 | — | Not yet recruiting | 2 | Dec 2026 | 1 | |
| LEAN-PRO GLP-1Effect of GLP-1 Receptor Agonists on Body Composition in Obesity: The Role of Dietary Protein Consumption in Muscle Mass Maintenance | GLP-1 / incretin class catch-all Obesity / overweight | BMI ≥30 | Not applicable | Recruiting | 2 | Mar 2028 | — | |
| ANGIOSAFE2Incretin-mimetic Hypoglycemic Drugs and Severe Retinopathy | GLP-1 / incretin class catch-all Type 2 diabetes | — | Not applicable | Unknown | 2 | Apr 2022 | 1 | |
| NCT03430284Multifactorial Intervention on Diabetes (MIDiab Study) | GLP-1 / incretin class catch-all Type 2 diabetes | — | Ph 4 | Unknown | 2 | Dec 2021 | — | |
| NCT03466021Effects of Liraglutide in Chronic Obstructive Pulmonary Disease | GLP-1 / incretin class catch-all, Liraglutide Obesity / overweight, Pulmonary Disease, Chronic Obstructive | BMI ≥27 | Ph 4 | Completed | 2 | May 2020 | 1 | |
| NCT03921242Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease | GLP-1 / incretin class catch-all Chronic kidney disease, Type 2 diabetes | HbA1c ≥6.5% | — | Completed | 2 | Aug 2023 | — | |
| NCT04126603Impact of Semaglutide on CD34+ EPC and Fat Derived MSC | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight, Type 2 diabetes | BMI 25-45 | Ph 4 | Completed | 2 | Oct 2023 | — | results |
| NCT05268627Endoscopic Ultrasound Guided Gastric Botulinum Toxin Injections Versus Glucagon Like Peptide 1 Receptor Agonist in Weight Loss | GLP-1 / incretin class catch-all, Liraglutide Obesity / overweight | BMI ≥30 | Not applicable | Unknown | 2 | Jan 2023 | — | |
| GALLOPGlucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies | GLP-1 / incretin class catch-all, Semaglutide Stroke | — | Ph 2 | Completed | 2 | Oct 2024 | 1 | |
| NCT06820047Sleeve Gastrectomy vs. Lifestyle & Medications: Impact on BMI Trajectory and Target Attainment in a Matched Cohort Study | GLP-1 / incretin class catch-all, Semaglutide Bariatric Surgery, Bariatric Surgery Candidate, Obesity / overweight | BMI ≥35 | — | Completed | 2 | Jul 2023 | 1 | |
| NCT07297238Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration. | GLP-1 / incretin class catch-all, Semaglutide Gastrointestinal (gastroparesis / short bowel / pancreatitis) | — | Not applicable | Recruiting | 2 | May 2026 | 14 | |
| NCT07360262Gastric Emptying Recovery After GLP-1 RA Cessation | GLP-1 / incretin class catch-all Perioperative / gastric aspiration risk | — | — | Completed | 2 | Dec 2025 | — | |
| NCT01945840Gut Hormones and Roux en Y Gastric Bypass | GLP-1 / incretin class catch-all Bariatric Surgery, Obesity / overweight, Prediabetes / glucose intolerance, Type 2 diabetes | HbA1c ≤9% | Not applicable | Recruiting | 1 | Oct 2028 | 6 | |
| NCT03363464Comparative Effectiveness of Empagliflozin in the US | GLP-1 / incretin class catch-all Type 2 diabetes | — | — | Active, not recruiting | 1 | May 2026 | 1 | |
| NCT03878706The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination | GLP-1 / incretin class catch-all, Liraglutide Cardiovascular disease, Heart failure, Type 2 diabetes | — | — | Recruiting | 1 | Dec 2026 | 26 | |
| BASIC2Brain Activation and Satiety in Children 2 | Exenatide, GLP-1 / incretin class catch-all Obesity / overweight | Age 10-12 | Ph 3 | Active, not recruiting | 1 | Aug 2025 | — | |
| BrainFoodHow Altered Gut-Brain-Axis Influences Food Choices: Part 2 (BrainFood) | GLP-1 / incretin class catch-all Obesity / overweight | BMI ≥30 | — | Active, not recruiting | 1 | Dec 2026 | — | |
| NCT06069622Role of Caveolin 1 (CAV-1) Deficiency in Response to Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Treatment | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight | BMI ≥30 | — | Recruiting | 1 | Oct 2026 | — | |
| NCT06132477Impact GLP-1 Agonists Following Bariatric | GLP-1 / incretin class catch-all, Semaglutide Bariatric Surgery, Obesity / overweight | BMI 30-80 | Ph 4 | Recruiting | 1 | Jul 2028 | 37 | |
| NCT06234111Semaglutide and Physical Activity for Obesity and Multimorbidity | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight | BMI ≥35 | — | Active, not recruiting | 1 | Oct 2026 | — | |
| NCT06271200Strategic Lifestyle Intervention for Metabolic Syndrome (SLIM-MET) | GLP-1 / incretin class catch-all, Semaglutide Metabolic syndrome, Obesity / overweight | BMI 27-45 | Not applicable | Recruiting | 1 | Oct 2027 | 24 | |
| Maigrir_OTEffect of Agonist GLP1 on Adipose Tissue in Patients Undergoing Bariatric Surgery | GLP-1 / incretin class catch-all Bariatric Surgery, Obesity / overweight | BMI ≥35 | Not applicable | Recruiting | 1 | Sep 2026 | — | |
| NCT06363747The Medically Reproducing Bariatric Surgery (MRB) II Study | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 2/3 | Active, not recruiting | 1 | Nov 2025 | 28 | |
| NCT06449235Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh | Albiglutide, Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide, Semaglutide Type 2 diabetes | HbA1c 7-10% | Ph 4 | Not yet recruiting | 1 | Apr 2025 | — | |
| NCT06467604CRAVE Study: Comparing Craving Responses and Diet Quality of GLP1 Receptor Agonist Users | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Obesity / overweight | BMI ≥30 | — | Active, not recruiting | 1 | Mar 2027 | — | |
| NCT06487832Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness | GLP-1 / incretin class catch-all, Semaglutide Healthy volunteers, Obesity / overweight | BMI 18.5-24.9 | Not applicable | Recruiting | 1 | Jul 2027 | — | |
| ESS-AKDThe Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease | GLP-1 / incretin class catch-all Renal impairment | eGFR ≥20 | Ph 2 | Recruiting | 1 | Jul 2027 | — | |
| NCT06581120GLP_1 RA Ultrasound Study | Dulaglutide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide Obesity / overweight, Perioperative / gastric aspiration risk, Type 2 diabetes | BMI ≥35 | — | By invitation | 1 | Jul 2026 | — | |
| NCT06682351Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention | GLP-1 / incretin class catch-all Obesity / overweight, Prediabetes / glucose intolerance, Type 2 diabetes | BMI ≥23 | Ph 4 | Not yet recruiting | 1 | Dec 2027 | — | |
| DECLARED-CTMenopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Diabetes | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight, Prediabetes / glucose intolerance, Reproductive / infertility, Type 2 diabetes | BMI ≥27 | Not applicable | Recruiting | 1 | Aug 2026 | — | |
| NCT06775093Effects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity | Beinaglutide, GLP-1 / incretin class catch-all Obesity / overweight, PCOS, Reproductive / infertility | BMI ≤35 | Not applicable | Not yet recruiting | 1 | Dec 2026 | — | |
| NCT06803888Bariatric Surgery vs. Semaglutide vs. Tirzepatide | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Bariatric Surgery Candidate, Obesity / overweight | BMI 35-65 | Ph 4 | Active, not recruiting | 1 | Jul 2027 | — | |
| NETsImpact of Antiglycemic & Immunosuppressive Therapies on NETosis in Diabetes & Kidney Disease (NETs - Neutrophil Traps) | GLP-1 / incretin class catch-all, Semaglutide Chronic kidney disease, Diabetes (other / unspecified), Healthy volunteers | — | — | Recruiting | 1 | Dec 2030 | — | |
| TRIM-IRResponse to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin Resistance | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight | BMI 30-40 | — | Recruiting | 1 | Aug 2026 | — | |
| ECS WeightWeight Loss Management in Endometrial Cancer Survivors | GLP-1 / incretin class catch-all Obesity / overweight, Oncology | BMI ≥30 | — | Recruiting | 1 | Oct 2028 | 19 | |
| NCT06889454Cardiovascular and Endothelial Markers During OGTT Before and at Six and Twelve Months Post-treatment in Women With PCOS | GLP-1 / incretin class catch-all PCOS | Female | — | Recruiting | 1 | Feb 2025 | — | |
| NCT06903923Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy | GLP-1 / incretin class catch-all, Liraglutide, Semaglutide Obesity / overweight | — | Ph 2 | Recruiting | 1 | Feb 2030 | — | |
| NCT06924697Effect of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Stimulation on Smoking Consumption in Type 2 Diabetes Patients | GLP-1 / incretin class catch-all, Semaglutide Alcohol / substance use, Type 2 diabetes | Male | Not applicable | By invitation | 1 | Jan 2026 | 32 | |
| OMICS in MASLDGLP-1 RA on Liver OMICS in MASLD | GLP-1 / incretin class catch-all MASH / NAFLD / liver fibrosis, Obesity / overweight, Type 2 diabetes | — | — | Not yet recruiting | 1 | Dec 2028 | — | |
| GA22POTS-FLOW: Interplay Between Gut Hormones and Autonomic Postprandial Blood Flow Regulation in Patients With POTS | GLP-1 / incretin class catch-all Healthy volunteers | — | Not applicable | Recruiting | 1 | Jun 2026 | 56 | |
| METSAFEMetabolic Surgery for Atrial Fibrillation Elimination | Dulaglutide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide, Tirzepatide Atrial fibrillation, Bariatric Surgery Candidate, Obesity / overweight | BMI 35-65 | Ph 4 | Not yet recruiting | 1 | Dec 2029 | — | |
| BETTER-GLP1Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity | GLP-1 / incretin class catch-all, Liraglutide, Semaglutide, Tirzepatide Feeding And Eating Disorders, Obesity / overweight | BMI ≥40 | — | Recruiting | 1 | Nov 2027 | — | |
| OPTIMALOptimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Bariatric Surgery Candidate, Hepatic impairment, Obesity / overweight | BMI 35-70 | Ph 4 | Recruiting | 1 | Feb 2029 | — | |
| STRONG-GLPStrength Training Response of Muscle in GLP-1 Users | GLP-1 / incretin class catch-all Obesity / overweight | — | Not applicable | Recruiting | 1 | Dec 2026 | — | |
| REFORMComparison of Body Composition Changes With Weight Loss Interventions | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Bariatric Surgery, Obesity / overweight | BMI 35-60 | — | Recruiting | 1 | Sep 2026 | — | |
| NCT07140055A Research Study to Evaluate BLX-7006 in Healthy Adults | GLP-1 / incretin class catch-all Healthy volunteers | BMI 20-35 | Ph 1 | Not yet recruiting | 1 | Apr 2026 | — | |
| NCT07163650Evaluating Anti-Obesity Medications 6 Months After Metabolic Surgery | GLP-1 / incretin class catch-all Bariatric Surgery, Obesity / overweight | BMI ≥28 | Ph 4 | Recruiting | 1 | Nov 2026 | — | |
| NCT07169136Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS) | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight, PCOS | Female | — | Recruiting | 1 | Dec 2026 | 4 | |
| NCT07175805Pelvic Floor Disorder Symptoms in Women Seeking Weight Loss Therapy | GLP-1 / incretin class catch-all Bariatric Surgery Candidate, Obesity / overweight | BMI ≥30 | — | Not yet recruiting | 1 | Oct 2026 | — | |
| NCT07195994A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes | GLP-1 / incretin class catch-all, Semaglutide Prediabetes / glucose intolerance, Type 2 diabetes | HbA1c 6-6.5% | Not applicable | Recruiting | 1 | Sep 2026 | — | |
| NCT07202247Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Obesity / overweight, Oncology | BMI ≥30 | Ph 2 | Recruiting | 1 | Apr 2028 | — | |
| NCT07205432Phase I Study of XTL6001 Injection in Healthy and Obese Subjects | GLP-1 / incretin class catch-all Healthy volunteers, Obesity / overweight | BMI ≥18.5 | Ph 1 | Recruiting | 1 | Apr 2026 | — | |
| NCT07207148People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists | GLP-1 / incretin class catch-all, Semaglutide Multiple sclerosis, Obesity / overweight | BMI ≥24 | — | Recruiting | 1 | Apr 2028 | 14 | |
| PROBIO-GLP1Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA Treatment | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Obesity / overweight | BMI ≥30 | Not applicable | Not yet recruiting | 1 | Apr 2027 | — | |
| NCT07223216Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants | GLP-1 / incretin class catch-all Obesity / overweight | BMI 25-40 | Ph 1 | Active, not recruiting | 1 | May 2026 | — | |
| NCT07224880Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists | GLP-1 / incretin class catch-all Obesity / overweight | — | — | Recruiting | 1 | Jan 2026 | 2 | |
| BICEPBody Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment | GLP-1 / incretin class catch-all Obesity / overweight | — | Not applicable | Recruiting | 1 | Jun 2027 | 9 | |
| NCT07271043Nutrition+: Effect of a High-Protein Diabetes Formula on Body Composition in Type 2 Diabetes Patients Treated With Incretin Mimetics | GLP-1 / incretin class catch-all Obesity / overweight, Type 2 diabetes | BMI ≥25 | Not applicable | Recruiting | 1 | Nov 2026 | — | |
| GLIMMERImpact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight, Type 2 diabetes | — | — | Recruiting | 1 | Dec 2027 | — | |
| NCT07293325Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Obesity / overweight | BMI ≥30 | Not applicable | Recruiting | 1 | Apr 2027 | — | |
| ADIPO-CKDClinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD | Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide, Tirzepatide Chronic kidney disease, Obesity / overweight, Type 2 diabetes | — | — | Recruiting | 1 | Jul 2027 | 15 | |
| NCT07316816Stanford Pediatric Healthy Weight Index | GLP-1 / incretin class catch-all Bariatric Surgery Candidate, Obesity / overweight | — | Not applicable | Recruiting | 1 | Dec 2030 | — | |
| MAGvMEDSide-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight, Type 2 diabetes | BMI 30-40 | Not applicable | Recruiting | 1 | Jun 2027 | — | |
| BetaBeta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists | Dulaglutide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide Type 2 diabetes | BMI 23-45 | Ph 4 | Active, not recruiting | 1 | Dec 2027 | 11 | |
| IMPACT-MACSIMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight | BMI ≥27 | Not applicable | Recruiting | 1 | May 2030 | 8 | |
| NCT07411560A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese | CagriSema / cagrilintide, GLP-1 / incretin class catch-all Obesity / overweight | Female | Ph 1 | Recruiting | 1 | Jan 2027 | — | |
| NCT07419854Restoring Facial Volume After GLP-1 Weight Loss With Radiesse | GLP-1 / incretin class catch-all Obesity / overweight | BMI 24-32 | Ph 4 | Recruiting | 1 | Aug 2027 | 18 | |
| DIGRATDirect Measurement of Microstructure of Ingestive Behaviour After Initiation of GLP-1 Receptor Agonist Treatment at Maximum Dose (DIGRAT) | GLP-1 / incretin class catch-all, Semaglutide Healthy volunteers, Obesity / overweight | BMI ≥30 | — | Active, not recruiting | 1 | Aug 2026 | 11 | |
| DECODEDECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Healthy volunteers, Hypertension, Obesity / overweight | BMI 18.5-24.9 | Ph 4 | Not yet recruiting | 1 | Apr 2027 | — | |
| BRIDGE-BRA Bridging Study of Efsubaglutide Alfa in Healthy Adults in Brazil | GLP-1 / incretin class catch-all Healthy volunteers | BMI 18-28 | Ph 1 | Not yet recruiting | 1 | Aug 2026 | — | |
| NCT07546357AIManage Using an AI-driven CDS and Chatbot | GLP-1 / incretin class catch-all Diabetes (other / unspecified), Obesity / overweight | — | Not applicable | Not yet recruiting | 1 | Mar 2028 | — | |
| RAPID-CKDRapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) | GLP-1 / incretin class catch-all, Semaglutide Chronic kidney disease, Type 2 diabetes | eGFR 45-90 | Ph 4 | Not yet recruiting | 1 | Mar 2029 | 37 | |
| NCT07554417Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1 | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight | BMI ≥30 | Ph 4 | Not yet recruiting | 1 | Jun 2026 | — | |
| NCT07558603Evaluate the Safety and Efficacy of AGE Serum in Post-menopausal Patients on Hormone Replacement Therapy Taking Glucagon-like Peptide-1 Agonist | GLP-1 / incretin class catch-all Healthy volunteers | Female | Not applicable | Not yet recruiting | 1 | Aug 2026 | — | |
| NCT07566299Early GLP-1 Receptor Agonist and SGLT2 Inhibitor Add-On Strategies in Adults With Obesity, Type 2 Diabetes, Cardiovascular-Kidney-Metabolic Syndrome Stage 2-3, and Metabolic Dysfunction-Associated Steatotic Liver Disease | GLP-1 / incretin class catch-all MASH / NAFLD / liver fibrosis, Metabolic syndrome, Obesity / overweight, Type 2 diabetes | BMI ≥27 | — | Not yet recruiting | 1 | Jun 2026 | 34 | |
| CARTIZCARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry | GLP-1 / incretin class catch-all, Tirzepatide Osteoarthritis, Psoriasis / psoriatic arthritis | — | — | Not yet recruiting | 1 | Nov 2027 | 13 | |
| NCT01232244Oxyntomodulin, Mechanisms of Action in Relation to Appetite, Food Intake, Gastric Emptying and Energy Expenditure. | GLP-1 / incretin class catch-all Healthy volunteers | Male | — | Completed | 1 | Jan 2012 | 1 | |
| NCT01434901The Effects of Bethanechol on Glucose Homeostasis | GLP-1 / incretin class catch-all Healthy volunteers, Prediabetes / glucose intolerance, Type 2 diabetes | HbA1c ≤9% | Ph 1 | Completed | 1 | Jul 2014 | 1 | |
| NCT01455441The Effects of Physical Training and GLP-1 Receptor Agonist Liraglutide Treatment in Patients With Type 2 Diabetes | GLP-1 / incretin class catch-all, Liraglutide Type 2 diabetes | BMI ≥25 | Ph 4 | Completed | 1 | Jun 2013 | — | |
| NCT01744236SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies | Exenatide, GLP-1 / incretin class catch-all, Liraglutide Healthy volunteers, Obesity / overweight, Type 2 diabetes | BMI 25-40 | Ph 4 | Completed | 1 | Aug 2015 | 6 | |
| NCT01847313The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease | GLP-1 / incretin class catch-all, Liraglutide Chronic kidney disease, Type 2 diabetes | — | Ph 3 | Completed | 1 | Nov 2015 | 25 | results |
| NCT01911468Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin | GLP-1 / incretin class catch-all, Liraglutide Obesity / overweight, PCOS | Female | Ph 4 | Completed | 1 | Oct 2012 | 1 | |
| NCT01972542The Usefulness of Postprandial Triglyceride for Assessment of Cardiovascular Risk | GLP-1 / incretin class catch-all Healthy volunteers, Prediabetes / glucose intolerance, Type 2 diabetes | HbA1c ≤10% | Not applicable | Completed | 1 | Jul 2015 | — | |
| NCT02057172Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes | Efpeglenatide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide Type 2 diabetes | HbA1c 7-10% | Ph 2 | Completed | 1 | Oct 2014 | 1 | |
| SAFEGUARDSafety Evaluation of Adverse Reactions in Diabetes | Exenatide, GLP-1 / incretin class catch-all Obesity / overweight, Type 2 diabetes | BMI 25-40 | Ph 4 | Completed | 1 | Oct 2015 | — | |
| NCT02187250PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome | GLP-1 / incretin class catch-all, Liraglutide Obesity / overweight, PCOS | Female | Ph 4 | Completed | 1 | Jun 2014 | 1 | |
| NCT02188303A Study of LY2944876 in Healthy Japanese and Non-Japanese Participants | GLP-1 / incretin class catch-all Healthy volunteers, Obesity / overweight | BMI 18.5-30 | Ph 1 | Terminated | 1 | Dec 2014 | — | results |
| LIONESSLiraglutide to Improve corONary Haemodynamics During Exercise streSS | GLP-1 / incretin class catch-all, Liraglutide Cardiovascular disease | — | Ph 2 | Completed | 1 | Mar 2015 | 2 | |
| NCT02324842Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients | GLP-1 / incretin class catch-all, Liraglutide Type 2 diabetes | HbA1c 7-10% | Not applicable | Completed | 1 | Mar 2018 | 2 | results |
| CGH-LiNASHComparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults | GLP-1 / incretin class catch-all, Liraglutide Bariatric Surgery, MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI ≥27.5 | Ph 3 | Unknown | 1 | Dec 2017 | 1 | |
| EGRABIS1The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke | Exenatide, GLP-1 / incretin class catch-all Stroke | — | Ph 2 | Unknown | 1 | Aug 2023 | — | |
| EGRABINS1The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke Volunteers | Exenatide, GLP-1 / incretin class catch-all Healthy volunteers | — | Ph 2 | Completed | 1 | Feb 2017 | 1 | |
| NCT02846233Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy? | Albiglutide, Dulaglutide, GLP-1 / incretin class catch-all Obesity / overweight, Type 2 diabetes | BMI ≥30 | Not applicable | Completed | 1 | Dec 2018 | 3 | results |
| NCT02987348Clinical Outcomes of Exenatide Versus Basal Insulin | Exenatide, GLP-1 / incretin class catch-all Type 2 diabetes | — | — | Completed | 1 | Jun 2015 | 1 | |
| EXENDAEffects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus. | Exenatide, GLP-1 / incretin class catch-all Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 4 | Completed | 1 | Nov 2019 | 1 | |
| NCT03115424Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy | GLP-1 / incretin class catch-all, Liraglutide Bariatric Surgery, Obesity / overweight | — | Ph 3 | Completed | 1 | Oct 2023 | — | results |
| NCT03151005The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS | Exenatide, GLP-1 / incretin class catch-all, Liraglutide Obesity / overweight, PCOS | BMI ≥24 | Ph 4 | Completed | 1 | Apr 2021 | 12 | results |
| EXALTDoes Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence? | Exenatide, GLP-1 / incretin class catch-all Alcohol / substance use, Healthy volunteers | — | Ph 2 | Completed | 1 | Mar 2020 | 1 | |
| NCT03249506Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM) | GLP-1 / incretin class catch-all Cardiovascular disease, Type 2 diabetes | Established CVD | — | Completed | 1 | Nov 2017 | — | |
| BELIEVEBinge Eating Liraglutide Intervention | GLP-1 / incretin class catch-all, Liraglutide Feeding And Eating Disorders, Obesity / overweight | BMI 27-29.9 | Ph 3 | Terminated | 1 | Sep 2019 | — | results |
| NCT03331289Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria | Exenatide, GLP-1 / incretin class catch-all Type 2 diabetes | BMI 21-45 | Ph 4 | Completed | 1 | Mar 2022 | 1 | results |
| NCT03492580A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease | Albiglutide, Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide Cardiovascular disease, Type 2 diabetes | Established CVD | — | Completed | 1 | Apr 2018 | — | |
| NCT04020445Simplification of Complex Insulin Regimens With Preserving Good Glycemic Control in Type 2 Diabetes | GLP-1 / incretin class catch-all, Liraglutide Type 2 diabetes | HbA1c ≤7.5% | — | Completed | 1 | Jan 2022 | 1 | |
| NCT04034524Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin | GLP-1 / incretin class catch-all, Liraglutide Type 2 diabetes | — | — | Unknown | 1 | Dec 2020 | — | |
| VASGLP-1 and Oxyntomodulin Release in Relation to Diet in Type 2 Diabetes Patients. | GLP-1 / incretin class catch-all Obesity / overweight, Type 2 diabetes | BMI 25-35 | Not applicable | Completed | 1 | Dec 2017 | 1 | |
| NCT04114136Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | GLP-1 / incretin class catch-all Oncology | — | Ph 2 | Recruiting | 1 | Aug 2025 | 2 | |
| S-LITECombined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet | GLP-1 / incretin class catch-all, Liraglutide Obesity / overweight | BMI 32-43 | Ph 4 | Unknown | 1 | Nov 2019 | 61 | |
| NCT04135287Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM Patients | GLP-1 / incretin class catch-all Type 2 diabetes | BMI 18-45 | Ph 4 | Unknown | 1 | Mar 2023 | — | |
| NCT04184947Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists | Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide Type 2 diabetes | — | — | Completed | 1 | Dec 2018 | 1 | |
| BEYONDDurability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND) | GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide Type 2 diabetes | HbA1c ≥7.5% | Ph 4 | Completed | 1 | Sep 2020 | 3 | |
| NCT04295005A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists | GLP-1 / incretin class catch-all Type 2 diabetes | — | — | Completed | 1 | Sep 2021 | — | results |
| PHROGGPR119 Agonist for Hypoglycemia in Type 1 Diabetes | GLP-1 / incretin class catch-all Healthy volunteers, Type 1 diabetes | Healthy volunteers | Ph 2 | Completed | 1 | Aug 2023 | 18 | results |
| PB119Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects | Exenatide, GLP-1 / incretin class catch-all Type 2 diabetes | BMI ≤40 | Ph 3 | Completed | 1 | Mar 2022 | 1 | |
| NCT04504396Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy | Exenatide, GLP-1 / incretin class catch-all Type 2 diabetes | BMI ≤40 | Ph 3 | Completed | 1 | Sep 2022 | — | |
| NCT04876027GLP-1 RAs in Patients With Polycystic Ovary Syndrome (PCOS) | Dulaglutide, GLP-1 / incretin class catch-all Obesity / overweight, PCOS | BMI ≥24 | Ph 4 | Completed | 1 | Apr 2022 | — | |
| NCT04964388Effect of GLP-1 Receptor Agonists on Trabecular Bone Score | GLP-1 / incretin class catch-all Osteoporosis / bone, Type 2 diabetes | HbA1c 7-10% | Ph 2 | Terminated | 1 | May 2023 | — | results |
| NCT05093517Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM | GLP-1 / incretin class catch-all Type 2 diabetes | BMI 25-40 | Early Ph 1 | Completed | 1 | Mar 2022 | — | |
| SEMA-APWeekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care | GLP-1 / incretin class catch-all, Semaglutide Type 1 diabetes | HbA1c ≤11% | Ph 2/3 | Completed | 1 | Apr 2024 | 1 | |
| NCT05214573Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk | GLP-1 / incretin class catch-all Type 2 diabetes | — | — | Completed | 1 | Sep 2023 | 3 | results |
| NCT05284344The Impact of Glucotoxicity on Gastric Emptying in Chinese Patients With Newly Diagnosed Type 2 Diabetes | GLP-1 / incretin class catch-all Healthy volunteers, Type 2 diabetes | HbA1c ≥7% | — | Completed | 1 | Dec 2023 | 5 | |
| NCT05492305Glucagon-like Peptide 1 (GLP1) Receptor Agonists and Mental Health | Dulaglutide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide Obesity / overweight, Type 2 diabetes | — | — | Unknown | 1 | Jun 2023 | — | |
| STABLE Wt LossSemaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight | BMI ≥30 | Ph 4 | Completed | 1 | May 2025 | 1 | |
| LIBERATE-1Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant | Exenatide, GLP-1 / incretin class catch-all, Semaglutide Healthy volunteers, Obesity / overweight | BMI 27-40 | Ph 1 | Completed | 1 | Aug 2025 | — | |
| NCT05705388POSE2.0 With GLP-1 Agonist for Obesity Management | GLP-1 / incretin class catch-all, Liraglutide Obesity / overweight | BMI 30-40 | Not applicable | Unknown | 1 | Jan 2025 | — | |
| NCT05762744Pharmacogenomics of GLP1 Receptor Agonists | Exenatide, GLP-1 / incretin class catch-all Healthy volunteers | BMI 18-40 | Ph 1 | Terminated | 1 | Nov 2018 | 2 | results |
| NCT05788965Semaglutide in CFRD | GLP-1 / incretin class catch-all, Semaglutide Cystic Fibrosis, Diabetes (other / unspecified), Obesity / overweight | BMI ≥26 | Ph 2/3 | Completed | 1 | Dec 2024 | — | results |
| EMINENT-2A Trial to Evaluate Safety, Feasibility and Efficacy of the ReCET Procedure (EMINENT-2) | GLP-1 / incretin class catch-all, Semaglutide Type 2 diabetes | BMI 24-42 | Not applicable | Active, not recruiting | 1 | Mar 2025 | 1 | |
| NCT06000891A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570 | Dapiglutide, GLP-1 / incretin class catch-all Obesity / overweight | BMI 27-39.9 | Ph 1 | Terminated | 1 | Feb 2025 | — | |
| NCT06118203Semaglutide Use in Acute Pulmonary Embolism | GLP-1 / incretin class catch-all, Semaglutide Cardiovascular disease | — | — | Completed | 1 | Mar 2023 | 1 | |
| NCT06120556Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes | Dulaglutide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥25 | — | Completed | 1 | Oct 2023 | 3 | |
| NCT06142006The Diabetes Staging System in Patient Aligned Care Teams | GLP-1 / incretin class catch-all Cardiovascular disease, Chronic kidney disease, Obesity / overweight, Type 2 diabetes | BMI ≥27 | — | Unknown | 1 | Sep 2024 | 3 | |
| NCT06236672Impact of GLP-1 RAs Compared to Basal Insulin Start in Patients Living With Type 2 Diabetes and Chronic Kidney Disease | GLP-1 / incretin class catch-all Chronic kidney disease, Type 2 diabetes | HbA1c ≥7.5% | — | Completed | 1 | Nov 2023 | — | |
| NCT06273163Identifying Strategies to Curtail Weight Regain After GLP-1 Receptor Agonist Treatment Cessation | GLP-1 / incretin class catch-all Obesity / overweight | — | Not applicable | Terminated | 1 | Aug 2025 | — | |
| NCT06296511The Influence of Acute Moderate-intensity Continuous Exercise on Appetite Regulation | GLP-1 / incretin class catch-all Healthy volunteers | BMI 18.5-24.9 | Not applicable | Completed | 1 | Nov 2023 | 1 | |
| NCT06401746Body Surface Gastric Mapping in Patients on Semaglutide | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight, Type 2 diabetes | HbA1c ≥7% | — | Recruiting | 1 | Mar 2025 | 3 | |
| NCT06500130Effects of Liraglutide on Body Surface Gastric Mapping | GLP-1 / incretin class catch-all, Liraglutide Healthy volunteers | BMI 22-35 | Not applicable | Completed | 1 | Oct 2024 | — | |
| NCT06660134Strict Weight Management Based on GLP-1 RA for Ablation Outcomes in Overweight or Obese Patients with T2DM and AF | GLP-1 / incretin class catch-all Atrial fibrillation, Obesity / overweight, Type 2 diabetes | BMI ≥25 | Not applicable | Completed | 1 | Dec 2023 | — | |
| ACECRAVEThe Influence of Acute Continuous Exercise and Adiposity on Appetite Hormones and Neural Correlates of Visual Food Cues | GLP-1 / incretin class catch-all Healthy volunteers, Obesity / overweight | BMI 18.5-24.9 | Not applicable | Completed | 1 | Sep 2025 | — | |
| NCT06901648A Study of HS-20094 in Patients With T2DM | Dulaglutide, GLP-1 / incretin class catch-all Type 2 diabetes | BMI ≥22 | Ph 2 | Completed | 1 | Mar 2025 | — | |
| NCT06927401Evaluate the Detection of Retained Gastric Contents and Assess Safety Using the Flower Capsule Endoscopy in Healthy Individuals and GLP-1 Receptor Agonist Users | GLP-1 / incretin class catch-all Healthy volunteers, Perioperative / gastric aspiration risk | — | Not applicable | Not yet recruiting | 1 | Jun 2025 | 7 | |
| DA168A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Overweight/Obese Subjects | GLP-1 / incretin class catch-all Obesity / overweight | BMI ≥28 | Ph 2 | Completed | 1 | Dec 2025 | — | |
| GLaDUnderstanding Acute Dietary Changes After GLP-1 Agonist Treatment: The GLaD Feasibility Study | GLP-1 / incretin class catch-all Obesity / overweight, Type 2 diabetes | — | — | Completed | 1 | Jan 2026 | — | |
| IPMN-GLP1RAImpact of GLP-1 Receptor Agonists on Patients With IPMN | GLP-1 / incretin class catch-all Oncology | — | — | Not yet recruiting | 1 | Oct 2026 | 1 | |
| SIPPA-QH_HHC-2Digital Behavioral Therapy to Reduce Diabetes and Liver Disease Risk | GLP-1 / incretin class catch-all Prediabetes / glucose intolerance, Type 2 diabetes | HbA1c 5.8-6.5% | Not applicable | Not yet recruiting | 1 | Dec 2026 | 1 | |
| Re-CHARMRebalancing the Fat Content of the Heart and Muscles | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Not applicable | Recruiting | 1 | Jul 2028 | 25 | |
| FIDGETA Feasibility Study to Determine the Most Appropriate Digital Dietary Assessment Tool in Patients With Obesity Initiating GLP-1 Receptor Agonist Treatment | GLP-1 / incretin class catch-all Obesity / overweight | — | Not applicable | Completed | 1 | Mar 2026 | 4 | |
| NCT07280403Effect of a Low-carbohydrate Diet on Weight Loss in People Using the Injectable GLP-1 Agonist Semaglutide for Weight Loss | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight | BMI ≥26 | Not applicable | Completed | 1 | Oct 2025 | — | |
| NCT07281196Semaglutide Effects on Sleep Apnea in Patients With Type 2 Diabetes/Obesity and Comorbid Obstructive Sleep Apnea | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight, Sleep apnea | BMI ≥27 | — | Completed | 1 | Dec 2025 | — | |
| NCT07448519Colonic Delivery of DIM and Perilla Oil on Gut Hormones and Food Intake in Obesity | GLP-1 / incretin class catch-all Obesity / overweight | BMI 30-40 | Not applicable | Completed | 1 | Aug 2023 | — | |
| NCT07491835Effect of Lower Doses of Colonic Nutrient Supplementation on Appetite Hormones and Food Intake in Obese Adults | GLP-1 / incretin class catch-all Obesity / overweight | BMI 30-40 | Not applicable | Completed | 1 | Nov 2023 | 1 | |
| NCT07513259Pre-Diagnosis GLP-1 Receptor Agonist Use and Post-Cancer Mortality in Adults With Obesity and Type 2 Diabetes | GLP-1 / incretin class catch-all Obesity / overweight, Oncology, Type 2 diabetes | BMI ≥27 | — | Completed | 1 | Oct 2025 | 38 | |
| GLP-1-CANEffect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes | GLP-1 / incretin class catch-all, Loxenatide / PEG-loxenatide, Semaglutide Diabetic neuropathy, Obesity / overweight, Type 2 diabetes | BMI ≥24 | Ph 4 | Recruiting | 1 | Mar 2028 | 15 | |
| NCT07602803The Effect of GLP1 Agonists on Weight Loss in BBS Cohort in the UK | GLP-1 / incretin class catch-all Hypothalamic / syndromic obesity, Obesity / overweight | — | — | Completed | 1 | Apr 2026 | 1 | |
| NCT07611201The Effects of GLP-1 Receptor Agonists on Chemosensory Function and Ingestive Behavior | GLP-1 / incretin class catch-all Obesity / overweight | BMI ≥30 | — | Completed | 1 | May 2026 | 1 | |
| NCT00551343Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome | Exenatide, GLP-1 / incretin class catch-all Healthy volunteers, Hypothalamic / syndromic obesity | — | Not applicable | Completed | 1 | Sep 2008 | — | |
| NCT01043445-Oleoyl Glycerol is a GPR119 Agonist and Signals GLP-1 Release in Humans. | GLP-1 / incretin class catch-all Healthy volunteers | Male · Healthy volunteers | Not applicable | Completed | 1 | Mar 2010 | — | |
| NCT01451905GLP-1 Receptors in Normal Skin and Skin From Patients With Psoriasis | GLP-1 / incretin class catch-all, Liraglutide Obesity / overweight, Psoriasis / psoriatic arthritis | BMI ≥27 | Not applicable | Unknown | 1 | Dec 2012 | — | |
| NCT01452451Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus | Efpeglenatide, Exenatide, GLP-1 / incretin class catch-all Type 2 diabetes | HbA1c 7-10% | Ph 2 | Completed | 1 | Jun 2013 | — | |
| NCT01460069The Effect of Glucagon Like Peptide (GLP)-1 in Psoriasis | GLP-1 / incretin class catch-all, Liraglutide Obesity / overweight, Psoriasis / psoriatic arthritis | BMI ≥27 | Not applicable | Completed | 1 | May 2013 | — | |
| ZYD1A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZYD1, Following Subcutaneous Administration in Healthy Volunteers | GLP-1 / incretin class catch-all Healthy volunteers | — | Ph 1 | Completed | 1 | Mar 2012 | — | |
| NCT02617654Liraglutide Effect on Beta-cell Function in C-peptide Positive Type 1 Diabetes | GLP-1 / incretin class catch-all, Liraglutide Type 1 diabetes | — | Ph 2 | Completed | 1 | Sep 2020 | — | |
| NCT02735031Exenatide and Impaired Hypoglycaemic Awareness in Type 1 Diabetes | Exenatide, GLP-1 / incretin class catch-all Type 1 diabetes | — | Ph 2/3 | Completed | 1 | Mar 2018 | — | |
| EASEA Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey | GLP-1 / incretin class catch-all Type 2 diabetes | HbA1c 8-11% | Ph 4 | Completed | 1 | Dec 2017 | — | |
| NCT03598075Amylin and CGRP Head to Head Provocation in Migraine Without Aura Patients | GLP-1 / incretin class catch-all, Pramlintide Headache Disorders | — | Not applicable | Completed | 1 | Sep 2019 | — | |
| iPAVEImaging Pituitary ActiVation by Exendin | Exenatide, GLP-1 / incretin class catch-all Type 2 diabetes | — | Not applicable | Completed | 1 | Apr 2024 | — | |
| NCT03994549A Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570 | Dapiglutide, GLP-1 / incretin class catch-all Healthy volunteers | BMI 18.5-28 | Early Ph 1 | Completed | 1 | Nov 2020 | — | |
| NCT04151849Effects of Diabetes Medications on Adrenal Function and Intestinal Microbiota | GLP-1 / incretin class catch-all Obesity / overweight, Type 2 diabetes | BMI ≥32 | — | Completed | 1 | Jan 2023 | — | |
| NCT05037045Effect of Gene Polymorphisms on GLP-1 Receptor Agonists Response in Patients With T2DM | GLP-1 / incretin class catch-all Type 2 diabetes | BMI 20-35 | Not applicable | Completed | 1 | Oct 2023 | — | |
| NCT05578352The Exploreration of the Management for the Positive IAA in Patients With Type 2 Diabetes After Premix Insulin Therapy | GLP-1 / incretin class catch-all Type 2 diabetes | — | Not applicable | Unknown | 1 | Jan 2023 | — | |
| NCT05854979Effects of GLP-1 Agonists on Gastric Volume | GLP-1 / incretin class catch-all Diabetes (other / unspecified), Perioperative / gastric aspiration risk | HbA1c ≥6.5% | — | Completed | 1 | Apr 2024 | — | |
| ENDISNovel Therapeutics and Endothelial Dysfunction in T1DM Patients | GLP-1 / incretin class catch-all, Semaglutide Type 1 diabetes | HbA1c ≤9% | Ph 4 | Completed | 1 | Mar 2022 | — | |
| NCT05875636GLP-1 Receptor Agonist Use and Incidence of Retained Gastric Food on Endoscopy | GLP-1 / incretin class catch-all Perioperative / gastric aspiration risk | — | — | Completed | 1 | Aug 2024 | — | |
| GLUCOSE-MGHGLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH | GLP-1 / incretin class catch-all, Semaglutide Prediabetes / glucose intolerance | — | Ph 4 | Recruiting | 1 | May 2027 | — | |
| NCT06038734Using Point-of-Care-Ultrasound (POCUS) to Assess Gastric Contents Among Fasting Pre-operative Patients Taking GLP-1 Agonists. | GLP-1 / incretin class catch-all Perioperative / gastric aspiration risk | — | — | Completed | 1 | Apr 2024 | — | |
| NCT06182852The Effect of GLP-1 Receptor Agonist on Bone Metabolism in Patients With Diabetes Mellitus | GLP-1 / incretin class catch-all Type 2 diabetes | HbA1c ≥7.5% | — | Unknown | 1 | Dec 2024 | — | |
| NCT06256419Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM | Exenatide, GLP-1 / incretin class catch-all Type 2 diabetes | BMI 20-35 | Not applicable | Recruiting | 1 | Jan 2028 | — | |
| NCT06263595Semaglutide and Preoperative Residual Gastric Volumes | GLP-1 / incretin class catch-all, Semaglutide Perioperative / gastric aspiration risk | — | — | Completed | 1 | May 2025 | — | |
| NCT06654219Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) Agonist Prior to Anesthesia | GLP-1 / incretin class catch-all Perioperative / gastric aspiration risk | — | Not applicable | Recruiting | 1 | May 2026 | — | |
| GLP-2antBlocking of the Gut Hormone Receptor for Glucagon-like Peptide 2 (GLP-2) by the GLP-2 Receptor Antagonist GLP-2(3-33) | GLP-1 / incretin class catch-all Healthy volunteers | BMI 19-28 | Not applicable | Completed | 1 | Sep 2024 | — | |
| NCT07096739Tolerance of a High Protein Nutrition Shake in Individuals on GLP-1 | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight | BMI ≥27 | Not applicable | Completed | 1 | Sep 2025 | — | |
| NCT07107334A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia | GLP-1 / incretin class catch-all, Liraglutide, Semaglutide, Tirzepatide Obesity / overweight, Oncology | BMI ≥30 | Ph 2 | Recruiting | 1 | Nov 2028 | — | |
| NCT07140289Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) on Gastric Emptying | GLP-1 / incretin class catch-all Perioperative / gastric aspiration risk | — | — | By invitation | 1 | Jun 2027 | — | |
| NCT07220473Tirzepatide to Slow Biological Aging | GLP-1 / incretin class catch-all, Tirzepatide Obesity / overweight | BMI ≥30 | Ph 2 | Recruiting | 1 | Nov 2027 | — | |
| NCT07221461Assess Impact of Microdroplet Hyaluronic Acid Filler on Skin Quality in Patients on Glucagon-like Peptide-1 Agonists | GLP-1 / incretin class catch-all Healthy volunteers | Female | Ph 2 | Not yet recruiting | 1 | Jan 2026 | — | |
| NCT07249554Combination Therapy for Alcohol Use Disorder | GLP-1 / incretin class catch-all, Semaglutide Alcohol / substance use | — | Ph 2 | Not yet recruiting | 1 | Jul 2028 | — | |
| NCT07327281A Clinical Trial Evaluating TQF3250 Capsules in Healthy Adult Subjects | GLP-1 / incretin class catch-all Healthy volunteers | BMI 20-40 | Ph 1 | Recruiting | 1 | Dec 2026 | — | |
| NCT07539584Adiponectin in Patients With Metabolic Disorders | GLP-1 / incretin class catch-all, Liraglutide, Semaglutide MASH / NAFLD / liver fibrosis, Obesity / overweight, Type 2 diabetes | BMI 25-39.9 | Not applicable | Completed | 1 | Apr 2024 | — | |
| GLP-1Effects of Beginning a GLP1-Agonist Therapy on Residual Gastric Content and Gastric Emptying | GLP-1 / incretin class catch-all Perioperative / gastric aspiration risk | — | — | Not yet recruiting | 0 | Oct 2026 | — | |
| NCT06795360Weight Changes After Incretin-mimetics | GLP-1 / incretin class catch-all Obesity / overweight | — | Not applicable | Not yet recruiting | 0 | Nov 2031 | — | |
| NPO-OOPS-TKROptimization of Obesity for Total Knee Replacement With Glucagon-like Peptide-1 Receptor Agonist | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight, Osteoarthritis | BMI ≥27 | Early Ph 1 | Not yet recruiting | 0 | Jul 2027 | — | |
| aGLP1-GUSGastric Emptying in Healthy Volunteers and GLP-1 Agonist Users | GLP-1 / incretin class catch-all, Semaglutide Healthy volunteers, Perioperative / gastric aspiration risk | Healthy volunteers | — | Not yet recruiting | 0 | Dec 2026 | — | |
| NCT07179120Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Obesity / overweight, Reproductive / infertility | BMI ≥28 | Ph 2 | Not yet recruiting | 0 | Aug 2026 | — | |
| NCT07314528Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer | GLP-1 / incretin class catch-all Obesity / overweight, Oncology | BMI ≥25 | Ph 2 | Not yet recruiting | 0 | Sep 2028 | 12 | |
| NCT07382388A Real-World Study on the Impact of Weight Loss on Treatment Efficacy in Overweight/Obese Patients With Plaque Psoriasis | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Obesity / overweight, Psoriasis / psoriatic arthritis | — | — | Not yet recruiting | 0 | Dec 2027 | — | |
| SHAPE-ENDOSHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight, Oncology | BMI ≥40 | Ph 4 | Not yet recruiting | 0 | May 2027 | 19 | |
| NCT07609160Effectiveness of Combined GLP-1/GIP Dual Agonist Therapy and Structured Exercise on Skeletal Muscle Morphology, Quality, and Physical Function in Overweight and Obese Individuals | GLP-1 / incretin class catch-all, Tirzepatide Obesity / overweight | BMI ≥27 | Not applicable | Not yet recruiting | 0 | Nov 2027 | — | |
| NCT01055340A Study That Will Evaluate Ketogenesis and Glucose-Dependent Insulin Secretion Methodologies in Healthy Male Subjects (MK-0000-159)(COMPLETED) | GLP-1 / incretin class catch-all Healthy volunteers, Obesity / overweight | BMI 27-35 | Ph 1 | Completed | 0 | May 2010 | 2 | |
| NCT02971722a Study of JY09 in Chinese Healthy Subjects | GLP-1 / incretin class catch-all Healthy volunteers | BMI 18-28 | Ph 1 | Unknown | 0 | May 2017 | 2 | |
| SOCRATES-AFSemaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients | GLP-1 / incretin class catch-all, Semaglutide Atrial fibrillation, Obesity / overweight | BMI ≥30 | Ph 3 | Withdrawn | 0 | Jan 2024 | — | |
| NCT06057077Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus | GLP-1 / incretin class catch-all, Semaglutide Type 1 diabetes | — | Ph 1/2 | Unknown | 0 | Dec 2024 | 2 | |
| GLP1-SGLT2-CKMEarly Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3 | GLP-1 / incretin class catch-all Obesity / overweight, Type 2 diabetes | — | — | Completed | 0 | Jan 2026 | 51 | |
| NCT01767389Glucagon-like Peptide (GLP) Utilization and Safety | Exenatide, GLP-1 / incretin class catch-all, Liraglutide Type 2 diabetes | — | — | Completed | 0 | Dec 2013 | — | |
| ALFA-1The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate | Exenatide, GLP-1 / incretin class catch-all, Liraglutide Type 1 diabetes | — | Ph 2/3 | Unknown | 0 | Nov 2015 | — | |
| NCT06438874Type 2 Diabetes Post Exercise Arterial Stiffness | GLP-1 / incretin class catch-all Obesity / overweight, Type 2 diabetes | BMI 25-40 | Not applicable | Withdrawn | 0 | Nov 2024 | — | |
| NCT07360457GLP1 Analogues and the Risk of Osteoarthritis | GLP-1 / incretin class catch-all Osteoarthritis, Type 2 diabetes | — | — | Not yet recruiting | 0 | Dec 2026 | — |